{"symbol":"REGN","fiscalQuarter":"Q1-2023","reportDate":"2023-05-04","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2023","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.14%","keyNumbers":[{"metric":"EPS","actual":"$10.09","expected":"N/A","surprise":"+30.87%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They noted ongoing investments in R&D to drive future growth."],"summary":"Overall, management expressed confidence in their product pipeline. However, they acknowledged market challenges that could impact future performance."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported a strong earnings per share, exceeding expectations significantly. However, the stock fell by over 6% in reaction, likely due to the absence of revenue details and guidance. Investors may be cautious as the company navigates market challenges despite the positive EPS surprise.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2023 earnings: EPS beat expectations. Stock down 6.14%. Full breakdown."}}